INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) PTO Form 1449	Attorney Docket No. 044574-5131	Application No. 10/582,610
	Applicants: Bing MA *et al.*	Page 1 of 1
	Filing Date: September 20, 2007	Group Art Unit: 1644

U.S. PATENT DOCUMENTS

Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date
	1.	6,100,087	August 8, 2000	Rossi *et al.*	435	320.1	March 11, 1998
	2.	6,476,028	November 5, 2002	Bondinell *et al.*	514	243	August 8, 2000
	3.	6,528,625	March 4, 2003	Wu *et al.*	530	388.22	July 11, 1997
	4.	US 20030017979	January 23, 2003	Mack *et al.*	514	12	September 5, 2001

FOREIGN PATENT DOCUMENTS

		Document No.	Date	Country	Class	Sub-Class	Translation
	5.	EP 1623721	February 8, 2006	EPO	A61K	45/00	
	6.	EP 1661889	May 31, 2006	EPO	C07D	213/76	
	7.	WO 01/51077	July 19, 2001	WIPO	A61K	38/19	
	8.	WO 01/64213	September 7, 2001	WIPO	A61K	31/44	
	9.	WO 04/056809	July 8, 2004	WIPO	C07D	405/06	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

	10.	Algood *et al.* CCR5-deficient mice control Mycobacterium tuberculosis infection despite increased pulmonary lymphocytic infiltration. J. Immunol. 173:3287-3296 (2004).
	11.	Cartier *et al.* Chemokine-induced cell death in CCR5- expressing neuroblastoma cells. J. Neuroimmunol. 145:27-39 (2003).
	12.	Fraziano *et al.* Expression of CCR5 is increased in human monocyte-derived macrophages and alveolar macrophages in the course of in vivo and in vitro Mycobacterium tuberculosis infection. AIDS Res. Hum. Retroviruses. 15:869-74 (1999).
	13.	Huffilagle *et al.* Cutting edge: Role of C-C chemokine receptor 5 in organ-specific and innate immunity to Cryptococcus neoformans. J. Immunol. 163:4642-4646 (1999).
	14.	Johnston *et al.* Radiation-induced pulmonary fibrosis: examination of chemokine and chemokine receptor families. Radiat. Res. 157:256-265 (2002).
	15.	Katchar *et al.* Expression of Thl markers by lung accumulated T cells in pulmonary sarcoidosis. J. Intern. Med. 254:564-571 (2003).
	16.	Kunkel *et al.* Expression of the chemokine receptors CCR4, CCR5, and CXCR3 by human tissue-infiltrating lymphocytes. Am. J. Pathol. 160:347-355 (2002).
	17.	Luckow *et al.* Reduced intragraft mRNA expression of matrix metalloproteinases Mmp3, Mmpl2, Mmpl3 and Adam8, and diminished transplant arteriosclerosis in CCR5-deficient mice. Eur. J. Immunol. 34:2568-2578 (2004).
	18.	Nissinen *et al.* CCR3, CCR5, interleukin 4, and interferon- gamma expression on synovial and peripheral T cells and monocytes in patients with rheumatoid arthritis. J. Rheumatol. 30:1928-1934 (2003).
	19.	Santucci *et al.* Expansion of CCR5+ CD4+ T-lymphocytes in the course of active pulmonary tuberculosis. Eur. Respir. J. 24:638-643 (2004).
	20.	Wu *et al.* Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gpl20 binding and a single domain for chemokine binding. J. Exp. Med. 186:1373-1381 (1997).

Examiner	/Ilia Ouspenski/	Date Considered	02/01/2010

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /I.O./